NCT07261098Not yet recruitingPhase 2
The Efficacy and Safety of ARNI on the Outcome of Advanced Lung Cancer With Concurrent Hypertension
A Prospective Study of the Efficacy and Safety of Angiotensin Receptor-neprilysin Inhibitor in Patients With Advanced Lung Cancer and Concurrent Hypertension
Source: ClinicalTrials.gov · Last updated 3 Dec 2025
Brief summary (registry, in English)
Despite the rapid development of novel anti-cancer therapeutic agents and ensuing improved prognosis, lung cancer remains the leading cause of cancer-related death globally, of which the majority of mortality could be attributed to advanced lung cancer. Hypertension is frequently diagnosed among patients with advanced lung cancer, either a comorbidity or complication, and is associated with increased incidence of cardiac adverse events, such as heart failure, coronary artery disease, and cardiac arrhythmias, hence aggravating patients' prognosis. Sacubitril/valsartan, a combination of an angiotensin II receptor blocker and neprilysin inhibitor (ARNI), is a novel agent to treat HF and has been approved to treat hypertension in China, of which the cardio-protective effect has been widely acknowledged. Yet current knowledge remains lacking on the influence of ARNI on the prognosis of advanced lung cancer with concurrent hypertension. The present study aimed to investigate the prognostic value of ARNI in patients with advanced lung cancer and concurrent hypertension.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 21 Nov 2025
- Start date
- Jan 2026
- Primary completion date
- Dec 2027
- Lead sponsor
- Shanghai Chest Hospital
- Diseases
- High blood pressure, Lung cancer
- NCT number
- NCT07261098
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 200
- From Jan 2026 to the primary completion date, Dec 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Hypersensitivity to any component of ARNI
Lab values
- Severe renal dysfunction (eGFR\<30ml/min/1.73m2)
Other
- Predicted survival period less than 12 months
- Female patients if pregnant.
- Severe liver dysfunction (Child-Pugh C)
- Bilateral renal artery stenosis or solitary renal artery stenosis
- Refractory hyperkalemia
- Moderate or severe aortic stenolsis
- Obstructive hypertrophic cardiomyopathy
Who the study is looking for
- Able to provide written informed consent (ICF) and able to understand and comply with the study requirements and assessment schedule.
- Male or female aged ≥18 years and \< 80years at the time of signing the ICF.
- Histologically or cytologically confirmed advanced lung cancer (TNM III-TNM IV) based on the 8th edition of the AJCC staging system
- Patients were diagnosed hypertension before the diagnosis of advanced lung cancer
- ECOG performance status score ≤ 1.
- Adequate organ function during the screening period
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.